title: Surveillance in inflammatory bowel disease: chromoendoscopy and digital mucosal enhancement.
abstract: Patients with long-standing inflammatory bowel disease (IBD) have an increased risk of developing colorectal cancer. Performing periodic dysplasia screening and surveillance may diminish this risk. To date, chromoendoscopy is the only technique that has consistently yielded positive results in large, well-designed dysplasia-detection trials. Most major society guidelines endorse chromoendoscopy as an adjunct, accepted, or preferred dysplasia-detection tool. This review outlines the available endoscopic technologies for the detection of dysplasia in IBD, considers the evidence supporting their use, and assesses which modalities are ready for use in clinical practice.
authors.affiliation: Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, New York, NY 10029, USA. steven.naymagon@mountsinai.org
authors.forename: Steven
authors.initials: S
authors.lastname: Naymagon
authors.forename: James F
authors.initials: JF
authors.lastname: Marion
mesh_terms: D000236:Adenoma / Q000175:diagnosis*; D003113:Colonoscopy / Q000379:methods; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000209:etiology; D004396:Coloring Agents; D006801:Humans; D007203:Indigo Carmine; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000175:diagnosis*; D007413:Intestinal Mucosa / Q000473:pathology*; D008751:Methylene Blue; D018613:Microscopy, Confocal / Q000379:methods; D062048:Narrow Band Imaging / Q000379:methods; D061848:Optical Imaging / Q000379:methods
chemical_list: D004396:Coloring Agents; D007203:Indigo Carmine; D008751:Methylene Blue